Joseph P. Hazelton Net Worth

Mr. Joseph P. Hazelton biography

Joseph P. Hazelton is the Chief Bus. Officer at Dyadic International.

What's Mr Hazelton's mailing address?

Joseph's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL, INC., 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.

Insiders trading at Dyadic International

Over the last 5 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet und Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.

What does Dyadic International do?

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.

Dyadic International executives and stock owners

Dyadic International executives and other stock owners filed with the SEC include:

• Mark Emalfarb,
  President, Chief Executive Officer, Director
• Mark A. Emalfarb,
  Founder, CEO, Pres & Director
• Matthew Jones,
  Managing Director - Business Development and Licensing
• Ping Rawson,
  Chief Financial Officer, Chief Accounting Officer
• Matthew S. Jones,
  Managing Director of Bus. Devel. & Licensing
• Ronen Tchelet,
  Vice President of Research and Business Development
• Dr. Ronen Tchelet Ph.D.,
  VP of Research & Bus. Devel.
• Jack Kaye,
  Independent Director
• Arindam Bose,
  Independent Director
• Michael Tarnok,
  Independent Chairman of the Board
• Seth Herbst,
  Independent Director
• Barry Buckland,
  Independent Director
• Ana Gómez Rodriguez,
  Sec. of the Board
• Joseph P. Hazelton,
  Chief Bus. Officer
• Patrick K. Lucy,
  Director
• Trust Under Agreement Dated...,
  10% owner
• Joseph P Hazelton,
  Chief Business Officer